Pennsylvania Qualifying Conditions: Detailed Guide
About the Qualifying Medical Conditions
Below is information about each qualifying condition and the research that informed Pennsylvania's decision to include it in the state program per Act 16 of 2016.
Severe Chronic or Intractable Pain
Chronic pain is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on systematic reviews examining cannabinoid use among patients with chronic pain conditions.
Anxiety Disorders
Anxiety disorders are approved qualifying conditions under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on research examining cannabinoid use in patients with anxiety disorders.
Cancer
Cancer is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on research examining cannabinoid use among cancer patients experiencing treatment-related symptoms.
Epilepsy and Intractable Seizures
Epilepsy and intractable seizures are approved qualifying conditions under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included these conditions based on clinical trial research examining CBD in patients with treatment-resistant epilepsy.
Autism
Autism is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on research examining cannabis use among patients with autism spectrum disorder.
PTSD
PTSD is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on research examining cannabinoid use among patients with PTSD.
Opioid Use Disorder
Opioid Use Disorder is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on research examining cannabis as a potential harm reduction strategy.
Multiple Sclerosis
MS is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on clinical research examining cannabinoid use in patients with MS-related spasticity.
Parkinson's Disease
Parkinson's Disease is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on research examining cannabinoid use among Parkinson's patients.
Crohn's Disease and IBD
Crohn's Disease and IBD are approved qualifying conditions under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included these conditions based on clinical research examining cannabis use in IBD patients.
Chronic Hepatitis C
Chronic Hepatitis C is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on research examining cannabis use among patients undergoing antiviral treatment.
ALS
ALS is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on research surveying ALS patients about symptom management.
Tourette Syndrome
Tourette Syndrome is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on research examining THC use in patients with Tourette's.
Huntington's Disease
Huntington's Disease is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016 as determined by the Pennsylvania Department of Health.
HIV/AIDS
HIV/AIDS is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on research examining cannabinoid use among HIV/AIDS patients.
Glaucoma
Glaucoma is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on early research examining the relationship between cannabinoids and intraocular pressure.
Sickle Cell Anemia
Sickle Cell Anemia is an approved qualifying condition under Pennsylvania's medical marijuana program per Act 16 of 2016. Pennsylvania included this condition based on research examining cannabis use among sickle cell patients.
Other Conditions
Neuropathies, Neurodegenerative Diseases, Dyskinetic and Spastic Movement Disorders, Damage to the Nervous Tissue of the Central Nervous System, and Terminal Illness are approved qualifying conditions under Pennsylvania's medical marijuana program per Act 16 of 2016 as determined by the Pennsylvania Department of Health.
Medical Disclaimer
This page provides information about Pennsylvania's qualifying conditions for medical cannabis per Act 16 of 2016. The inclusion of a condition in Pennsylvania's program does not constitute medical advice or a guarantee of therapeutic benefit. Individual results vary. Potential side effects may include dizziness, sedation, and cognitive changes. Always consult a healthcare provider before starting treatment.